Richard G. Stock
Icahn School of Medicine at Mount Sinai
CancerInternal medicineRadiologyUrologySurgeryOncologyStage (cooking)External beam radiotherapyProstateBrachytherapyHormonal therapyProstate brachytherapyProstatectomyProstate cancerProstate-specific antigenImplantLow-Dose Rate BrachytherapyNuclear medicineRadiation therapyMedicine
389Publications
72H-index
9,543Citations
Publications 389
Newest
#1Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 19
#2R. Jeffrey Karnes (Mayo Clinic)H-Index: 70
Last. Robert T. Dess (UM: University of Michigan)H-Index: 16
view all 0 authors...
Importance null The optimal management strategy for high-risk prostate cancer and additional adverse clinicopathologic features remains unknown. null Objective null To compare clinical outcomes among patients with high-risk prostate cancer after definitive treatment. null Design, Setting, and Participants null This retrospective cohort study included patients with high-risk prostate cancer (as defined by the National Comprehensive Cancer Network [NCCN]) and at least 1 adverse clinicopathologic f...
Source
Source
#1Rebecca G. Philipson (UCLA: University of California, Los Angeles)H-Index: 1
#2Tahmineh Romero (UCLA: University of California, Los Angeles)H-Index: 5
Last. Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 19
view all 52 authors...
Abstract The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent HRPCa who previously received either external beam radiation therapy (EBRT, n = 654, 67%) or EBRT + brachytherapy (EBRT + BT, n = 324, 33%) across 15 institutions from 1997 to 2015. In men who did not die, median follow...
1 CitationsSource
#1Chad TangH-Index: 32
#2Jeremiah SandersH-Index: 7
Last. Francis J. SullivanH-Index: 15
view all 0 authors...
Source
#1Howard D. ThamesH-Index: 89
#2Chad TangH-Index: 32
Last. Charles CattonH-Index: 71
view all 0 authors...
Source
#1Davood Roshan (National University of Ireland, Galway)H-Index: 2
#2Kieran Joyce (National University of Ireland, Galway)H-Index: 1
Last. Francis J. Sullivan (National University of Ireland, Galway)H-Index: 15
view all 6 authors...
PURPOSE To determine if Live Implant Dosimetry (LIDO) utilizing intraoperative transrectal ultrasound (TRUS) is equivalent to postimplant CT dosimetry (either day 0 or day 30) in patients with localized prostate cancer (PC) treated with low dose rate (LDR) prostate seed brachytherapy. METHODS AND MATERIALS The treated population consisted of 628 men with localized (T1-T2) PC. All d'Amico risk categories (low, intermediate, and high) were included, and 437 patients were treated with monotherapy (...
Source
#1Nicola Rares Franco (Ghent University Hospital)H-Index: 1
#1Nicola Rares Franco (Ghent University Hospital)
Last. Tiziana RancatiH-Index: 27
view all 43 authors...
AIM To identify the effect of single nucleotide polymorphism (SNP) interactions on the risk of toxicity following radiotherapy (RT) for prostate cancer (PCa) and propose a new method for polygenic risk score incorporating SNP-SNP interactions (PRSi). MATERIALS AND METHODS Analysis included the REQUITE PCa cohort that received external beam RT and was followed for 2 years. Late toxicity endpoints were: rectal bleeding, urinary frequency, haematuria, nocturia, decreased urinary stream. Among 43 li...
Source
#1Anthony D. Nehlsen (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 1
#2Kunal K. Sindhu (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 8
Last. Richard G. Stock (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 72
view all 5 authors...
Abstract Purpose Rectal hydrogel spacers have been shown to decrease rectal radiation dose and toxicity. In this study, we compared prostate and rectal dosimetry and acute toxicity outcomes in patients who had and had not received a rectal hydrogel spacer prior to combination therapy with external beam radiotherapy and low-dose-rate brachytherapy. Materials and Methods All patients with intermediate-risk and high-risk prostate cancer who received combination therapy at our institution were ident...
Source
#1William H. Smith (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 2
#2Jamie A. CesarettiH-Index: 30
Last. Richard G. Stock (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 72
view all 5 authors...
Abstract Purpose We sought to describe the safety and efficacy of salvage low dose rate (LDR) brachytherapy for local prostate cancer recurrence following definitive RT. Materials and Methods We included patients from two prospectively maintained institutional databases who underwent salvage LDR brachytherapy for biopsy confirmed intra-prostatic recurrence following primary RT. All patients were without evidence of metastatic disease. Freedom from biochemical failure (FFbF), prostate cancer spec...
Source
#1Andrew W. Smith (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 1
#2Benjamin A. Greenberger (Thomas Jefferson University)H-Index: 6
Last. Richard G. Stock (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 72
view all 4 authors...
As a single organ distributed diffusely throughout the body, bones represent both a unique challenge and unique opportunity for the treatment of symptomatic metastatic disease. While the multifocality of bone metastases often prevents effective complete treatment with focal radiotherapy, the similar pathophysiology of these diffuse sites of disease opens the door to targeted systemic therapy. The relatively rapid dose fall-off from beta- or alpha-emitting particles, if correctly and reliably tar...
Source